studies

non squamous - mNSCLC - L1 - Wild Type (WT), atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMpower-150 (ABCP vs BPC WT), 2018 0.78 [0.64; 0.96] 0.78[0.64; 0.96]IMpower-150 (ABCP vs BPC WT), 201810%696NAnot evaluable progression or deaths (PFS)detailed resultsIMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 0.51 [0.38; 0.68] IMpower-150 (ABCP vs BPC WT), 2018 0.62 [0.52; 0.74] 0.58[0.49; 0.70]IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 2018221%976moderatenot evaluable objective responses (ORR)detailed resultsIMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 1.96 [1.20; 3.19] IMpower-150 (ABCP vs BPC WT), 2018 1.88 [1.38; 2.55] 1.90[1.47; 2.46]IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018, IMpower-150 (ABCP vs BPC WT), 201820%964moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:37 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 176 - treatments: 1070